Join us on  LinkedIn, Twitter, Facebook, YouTube, ResearchGate, SlideShare, Flickr, and share comments. 

Read Senology Newspaper daily

Literature Selection

• Kroenke CH et al.: "High- and Low-Fat Dairy Intake, Recurrence, and Mortality After Breast Cancer Diagnosis", J Natl Cancer Inst. 2013 Mar 14. [Epub ahead of print]
• Foca F et al.: "Decreasing incidence of late-stage breast cancer after the introduction of organized mammography screening in Italy", Cancer. 2013 Mar 15 [Epub ahead of print]
• Dawson SJ et al.: "Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer", N Engl J Med. 2013 Mar 13. [Epub ahead of print]
• Schindlbeck C et al.: "Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients", J Cancer Res Clin Oncol. 2013 Mar 23. [Epub ahead of print]
• Harbeck N et al.: "Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients", Eur J Cancer. 2013 Mar 12 [Epub ahead of print]
• Darby SC et al.: "Risk of ischemic heart disease in women after radiotherapy for breast cancer", N Engl J Med. 2013 Mar 14;368(11):987-98
• Donker M et al.: "Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: Identification rate and nodal outcome", Eur J Cancer. 2013 Mar 19 [Epub ahead of print]

Editorial

• "Prognostic and predictive value of tumor-infiltrating lymphocytes in node-positive breast cancer", Sherene Loi, Translational Breast Cancer Genomics Lab, Division of Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
   
  ""We and others have previously shown that an immune signal can influence prognosis and response to treatment, particularly “immunogenic therapies” in specific breast cancer subtypes, such as those estrogen receptor (ER)-negative and/or overexpressing the HER2/neu oncogene. To validate this further and determine immunity could be a clinically relevant biomarker, we evaluated the association between quantity of tumor infiltrating lymphocytes (TILs) in a breast cancer, prognosis and prediction of response to anthracyline chemotherapy in a large clinical trial in over 2000 primary breast cancers and long term follow-up data. We found that TILs were strongly associated with a good prognosis in the triple negative breast cancer (TNBC: ER, PGR, and HER2-negative) subtype - even node positive TNBCs had an excellent survival if they were observed to have high amounts of TILs at diagnosis (read more)".
  (Commentary on:  Loi S et al.: "Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98", J Clin Oncol. 2013 Jan 22. [Epub ahead of print])

Questions and Answers 

• Breast Surgery Workshop Summary - The Center for Natural Breast Reconstruction, Mount Pleasant, SC, USA

Fragments of History

• 1976 - Gianni Bonadonna (Milan, Italy): "Our data indicate that patients with potentially curable breast cancer and with positive axillary lymph nodes at the time of mastectomy show a statistically significant reduction in recurrence rate during the first 27 months after radical mastectomy when treated with cyclic prolonged combination chemotherapy. At present, the advantage of CMF appears statistically evident in all subgroups of patients" (Bonadonna G et al.: "Combination chemotherapy as an adjuvant treatment in operable breast cancer ", N Engl J Med. 1976 Feb 19;294(8):405-10)

Calendar of Events

• 5th IMPAKT Breast Cancer Conference, May 2-4, 2013, Brussels, Belgium
• Precision Medicines in Breast Cancer, May 9-10, 2013, London, UK
• 15th Milan Breast Cancer Conference, June 20-21, 2013, Milan, Italy
• 3rd World Congress on Cancer Science & Therapy, October 21-23, 2013,  San Francisco, CA, USA - in partnership with Senology
• 9th Meet the Professor. Advanced International Breast Cancer Conference (AIBCC), November 11-13, Padova, Italy - under the Patronage of Senology
• Update in Breast Imaging, 22-23 November, Ostend, Belgium

HEALTHCARE INDUSTRY NEWS   Bracco receives MHRA approval for expanded labeling of MultiHance® (gadobenate dimeglumine) in magnetic resonance imaging of the breast  Press release - Milan (Italy), March 11, 2013 - " Bracco receives MHRA approval for expanded labeling of gadobenate dimeglumine in Magnetic Resonance Imaging of the breast. - MultiHance®, the highest relaxivity contrast agent for MRI of the central nervous system, is now approved for breast MRI " (read more)

Literature Selection

• Rasmussn-Torvik LJ et al.: "Ideal Cardiovascular Health is Inversely Associated with Incident Cancer: The Atherosclerosis Risk in Communities Study", Circulation. 2013 Mar 18. [Epub ahead of print]
• Neef HP et al.: "Outcome after repeat resection of liver metastases from colorectal cancer", Int J Colorectal Dis. 2013 Mar 7. [Epub ahead of print]
• Park JH et al.: "The beneficial effect of palliative resection in metastatic colorectal cancer", Br J Cancer. 2013 Mar 12 [Epub ahead of print]
• Verhoven B et al.: "Ki-67 Is an Independent Predictor of Metastasis and Cause-Specific Mortality for Prostate Cancer Patients Treated on Radiation Therapy Oncology Group (RTOG) 94-08", Int J Radiat Oncol Biol Phys. 2013 Mar 5 [Epub ahead of print]
• Bomers JG et al.: "MR Imaging-guided Focal Cryoablation in Patients with Recurrent Prostate Cancer", Radiology 2013 Mar 22 [Epub ahead of print]
• Mukozu T et al.: "Serum VEGF as a Tumor Marker in Patients with HCV-related Liver Cirrhosis and Hepatocellular Carcinoma", Anticancer Res. 2013 Mar;33(3):1013-21
• Yeon JS et al.: "Thyroid Nodules with Initially Nondiagnostic Cytologic Results: The Role of Core-Needle Biopsy", Radiology 2013 Mar 22 [Epub ahead of print]

Discussion

•   "Intermittent versus continuous androgen deprivation in prostate cancer " -  Share your opinion on  LinkedIn

Questions and Answers 

• Kidney Cancer Workshop Summary - with Robert Figlin, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
• Lung Cancer Workshop Summary - with Joel Neal, Stanford University, Stanford, CA, USA
• Radiation Oncology Workshop Summary - with Matt Katz, Radiation Oncology Associates, Londonderry, NH, USA
• Melanoma Workshop Summary - with Alan Spatz, McGill University, Montréal, QC, Canada